*Sponsored by Nutriband Inc.
Krypton Street Adds Nutriband Inc. (NASDAQ: NTRB) To The Top
Of Today's Early Watchlist—Tuesday, October 28, 2025
Tap Now For Full (NTRB) Coverage Sent Directly
To Your Mobile Device
Here's What We Can Tell You Right Now:
Small Float: With Fewer Than 6M Shares Available, (NTRB)'s Small Float
Could Lead To The Potential For Big Moves If Demand Begins To Shift.
Recent Momentum: Over The Past Two Months, (NTRB) Has Moved
Approximately 47%, Which Could Reflect Growing Attention.
Analyst Coverage: Noble Capital Markets Recently Reaffirmed A $15
Target On (NTRB), Which Suggests Over 100% Upside Potential.
Take A Look At (NTRB) While It's Still Early…
October 28, 2025
Momentum Watch | (NASDAQ: NTRB) Makes An Approx. 10% Move After FDA Meeting Dear Reader, Momentum potential is building fast this morning—and Nutriband Inc. (NASDAQ: NTRB) is right at the center of it. (NTRB) reached $7.88 on an approximate 10% move—after announcing it successfully completed its FDA meeting for its lead program, the AVERSA™ Fen-tan-yl abuse-deterrent patch.
The company received final written guidance from the FDA as it moves toward an IND filing and Human Abuse Potential (HAP) clinical study. The FDA also confirmed the 505(b)(2) regulatory pathway for the program and provided feedback on chemistry, manufacturing, and validation plans—critical steps as (NTRB) works to bring what could become the world's first abuse-deterrent Fen-tan-yl patch to market. The Agency acknowledged the importance of addressing Fen-tan-yl patch misuse and pledged continued collaboration as (NTRB) advances development with its partner, Kindeva, a global leader in transdermal manufacturing systems. Sometimes the market gives you a signal that's hard to ignore. The pieces start falling into place—the data, the timing, the execution—and a clear picture begins to emerge. This morning, that picture points to Nutriband Inc. (NASDAQ: NTRB)—now topping our watchlist for Tuesday, October 28, 2025. But keep in mind, (NTRB) has less than 6M shares listed in its float according to MarketWatch. When floats are this small, the potential exists for big moves if demand begins to shift. Over the past two months, (NTRB) has made an approximate 47% move, from $5.85 on September 10 to $8.63 on October 8. Just days ago, Robert LeBoyer, Senior Vice President and Biotechnology Analyst at Noble Capital Markets, reiterated his $15 target on the company—implying over 100% potential upside from recent levels. 
Adding to this momentum, on October 27, 2025, (NTRB) announced that Co-Founder Gareth Sheridan has returned as Chief Executive Officer, stepping back into leadership to guide the company through the final stretch toward its 2026 NDA filing for AVERSA™ Fen-tan-yl.
Sheridan's return restores founding leadership at a pivotal moment, as (NTRB) moves closer to what could become the world's first FDA-approved abuse-deterrent opioid patch.
The company projects peak U.S. sales potential of $80M–$200M, with plans to expand access across major global healthcare markets. Nutriband Inc. (NASDAQ: NTRB) is a transdermal pharmaceutical company developing its proprietary AVERSA™ abuse-deterrent technology, designed to make commonly misused pain patches significantly harder to abuse while improving safety and patient comfort. Rather than creating new chemical compounds, (NTRB) enhances existing FDA-approved dr-ugs by embedding its patented deterrent layers into proven transdermal delivery systems. Under Sheridan's renewed leadership, (NTRB) continues to operate with a structure built for both innovation and sustainability. The company has three wholly owned subsidiaries—4P Therapeutics, Pocono Pharmaceuticals, and Active Intelligence—that collectively generate revenue and help offset research and development costs. - 4P Therapeutics manages Nutriband's clinical and regulatory programs.
- Pocono Pharmaceuticals provides contract manufacturing for clients ranging from small firms to global consumer brands like Reebok and KT Tape.
- Active Intelligence produces kinesiology and consumer health products, including a vitamin-based mosquito-repellent patch already approved for sale in Central America.
This diversified foundation provides operational stability and financial discipline, allowing (NTRB) to advance its pharmaceutical pipeline without constantly relying on new capital raises—an approach management believes helps preserve long-term shareholder value and minimize dilution. Lead Program: AVERSA Fen-tan-yl
(NTRB)'s lead focus, AVERSA Fen-tan-yl, aims to make powerful pain relief safer by preventing patch misuse and accidental exposure. The patch includes a protective layer made from harmless but highly unpleasant ingredients—deterrents that make tampering nearly impossible. To prepare for commercialization, (NTRB) partnered with Kindeva Dr-ug Delivery, a global leader in transdermal manufacturing, to complete large-scale production. This milestone confirms the company's ability to produce commercial-ready batches and move toward final testing. The next major step is a human study comparing AVERSA Fen-tan-yl with standard patches to measure resistance to tampering or extraction. Following FDA meetings in September 2025, (NTRB) expects the study to begin in early 2026, with an FDA submission later in the year and potential approval by late 2026 or 2027. Adding to this progress, (NTRB) signed an agreement on October 10, 2025, with Brand Institute, Inc., the world leader in dr-ug naming and identity development, to create the official brand name and visual identity for AVERSA™ Fen-tan-yl—another signal that commercial readiness is near. Market Outlook and Sales Potential
A study commissioned by Advanced Health estimated that AVERSA Fen-tan-yl could bring in around $200M in annual sales after launch. If regulators decide that all pain patches must include similar safety technology—something that's possible once AVERSA proves its value—sales could grow toward $800M a year. The same analysis also suggested that insurers may pay about 20% more for a safer, branded patch because it lowers the risk of patient harm and accidental exposure. This potential comes at a time when many doctors have scaled back on prescribing Fen-tan-yl patches due to misuse concerns, leaving some chronic-pain patients with fewer options. (NTRB)'s solution could help restore confidence among physicians and insurers by offering a patch that provides the same relief but with far fewer safety risks. Intellectual Property and Platform Expansion
(NTRB) has built a strong foundation of patents that protect its technology in more than 45 countries, and new filings are expected to extend that protection until 2045. The company doesn't view AVERSA as just one product—it's a platform that can be applied to other medications that face similar risks of misuse. Next in line are two related patches: - AVERSA Buprenorphine, aimed at treating opioid dependence and chronic pain.
- AVERSA Methylphenidate, designed for attention-deficit disorders.
Because the AVERSA system has already been proven, these follow-on products should move through development much faster—possibly within 6–12 months of the Fen-tan-yl patch approval. Looking further ahead, (NTRB)'s team is also researching a needle-free insulin patch for people with type 2 diabetes. While still early in development, it shows how the same transdermal technology could eventually reach beyond pain management. Near-Term Milestones
Over the next 12 to 18 months, (NTRB)'s progress will center around a few key steps: - Receiving formal FDA feedback from the September 2025 meeting.
- Launching the human abuse study in early 2026 and reviewing results within about three months.
- Preparing the FDA filing later in 2026 with manufacturing data from Kindeva.
- Beginning work on the next AVERSA-based patches for buprenorphine and methylphenidate.
Together, these milestones make 2026 a potentially defining year for (NTRB)—one that could move the company from research mode to full commercial readiness. See Why (NTRB) Is Topping Today's Watchlist
—Tuesday, October 28, 2025 1. Recent Momentum: over the last two months, (NTRB) has made an approximate 47% move, signaling the potential for growing attention.
2. Small Float: with fewer than 6M shares in its float, (NTRB) has the potential for big moves if demand begins to shift. 3. Leadership Back in Place: the return of Co-Founder Gareth Sheridan brings experienced leadership as (NTRB) approaches its 2026 NDA milestone. 4. Regulatory Milestones Ahead: upcoming FDA feedback and a planned 2026 filing could mark a pivotal phase in (NTRB)'s commercialization path. 5. Scalable Technology Platform: beyond Fen-tan-yl, (NTRB)'s AVERSA platform can be adapted for other high-need therapies, expanding future pipeline potential. 6. Operational Stability Built-In: through its revenue-generating subsidiaries, (NTRB) maintains financial discipline that supports long-term growth without heavy dilution. 7. Analyst Coverage: Noble Capital Markets recently reiterated a $15 target on (NTRB), which suggests over 100% upside potential from its current range. Take A Look At (NTRB) While It's Still Early…
When you take a closer look, it's easy to see why attention around (NTRB) continues to build. A small float of under 6M shares, recent 47% approximate move, and a reaffirmed $15 target from Noble Capital Markets have placed the company firmly on the radar. With Co-Founder Gareth Sheridan back at the helm and key FDA milestones on the horizon, (NTRB) enters a phase that could define its next chapter. Add in a scalable AVERSA™ platform designed for multiple therapies and a business model supported by real operating revenue, and you have a company built on more than just potential—it's built on progress. (NTRB) has our full attention heading into today's session—make sure it's on your screen while it's still early. Keep an eye out for my next update, it could be here any moment. Sincerely,
Alex Ramsay
Co-Founder / Managing Editor Krypton Street
| 
Tidak ada komentar:
Posting Komentar